Mochi Health: a starter guide that doesn’t waste your time

Mochi Health: a starter guide that doesn’t waste your time

By [Writer name] · Last reviewed July 2025 · 8 min read

You’re considering Mochi Health, or maybe you already signed up and you’re staring at the app wondering what happens next. The short answer: Mochi is a GLP-1 telehealth platform that prescribes semaglutide or tirzepatide, pairs you with a dietitian, and charges a membership fee on top of medication costs. Whether that’s worth it depends entirely on what you actually need from a weight loss program.

What is Mochi Health and how does it work?

Mochi Health is a telehealth obesity medicine practice. You pay a monthly membership (around $99), complete an intake form, get matched with a provider, and if you’re eligible, receive a prescription for a GLP-1 medication. The medication is compounded and shipped from a pharmacy, not dispensed at retail.

The platform positions itself as a full-care model, not just a prescription pipeline. That means you get access to dietitian coaching, behavior change curriculum, and lab work coordination alongside the medication piece. Whether you use those services is up to you, but they’re the main thing distinguishing Mochi from a bare-bones prescribe-and-ship service.

The GLP-1 medications prescribed are semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound). Mochi uses compounded versions sourced through licensed pharmacies. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% average body weight loss with semaglutide at 68 weeks in adults with obesity. That’s the clinical foundation the platform is built on.

How does Mochi compare to Noom and other GLP-1 platforms?

Mochi is closer to a medical practice than Noom. Noom started as a psychology-based behavior change app and added GLP-1 prescribing later. Mochi started as an obesity medicine practice and built the app around clinical care.

That distinction matters in practice. Noom’s core product is its curriculum and coaching. The medication piece is newer and the clinical infrastructure is less mature. Mochi’s core product is the provider relationship and the prescription. The behavior coaching exists, but the medical side is the main event.

Orderly Meds is another name that comes up in comparisons. It operates more like a direct pharmacy model with a lighter clinical layer. If you want the lowest-friction path to a prescription and you’re comfortable self-managing, that model works. If you want a dietitian checking in and a provider who’ll adjust your dose based on how you’re doing, Mochi is structured for that.

The honest answer is that none of these platforms are dramatically different in outcomes. What changes is how much hand-holding you get and what you pay for it.

What to do your first week on semaglutide

Your first week is almost entirely about managing expectations and minimizing nausea. The starting dose for compounded semaglutide is 0.25mg weekly. That dose is low enough that many people feel nothing. Some people feel everything.

Nausea, fatigue, and constipation are the three most common early side effects. The STEP 1 trial reported nausea in 44% of semaglutide participants, with most cases rated mild to moderate. It usually peaks in weeks 2 through 4 and improves significantly by week 8.

Practical things that actually help in week one:

• Inject on the same day each week, at the same time. Consistency matters more than the specific day.
• Eat smaller portions than you think you need. The appetite suppression isn’t fully active yet at 0.25mg, but your stomach is already more sensitive.
• Avoid high-fat meals the day of and the day after your injection. They amplify nausea.
• Stay hydrated. Constipation is underreported as a side effect and dehydration makes it worse.
• Don’t start a calorie-restricted diet simultaneously. You’re already making a significant physiological change. Stacking a 1,200-calorie protocol on top of week one semaglutide is a setup for feeling terrible.

The injection itself is subcutaneous, meaning into fat tissue, usually the abdomen or thigh. The needles are small. Most people find it far less intimidating than expected.

How does dose escalation work?

Standard semaglutide escalation runs 0.25mg for 4 weeks, then 0.5mg for 4 weeks, then 1.0mg, then 1.7mg, then 2.4mg. That’s the schedule used in the STEP trials. Most telehealth platforms including Mochi follow this or a close variation.

The escalation exists to let your GI tract adapt. Jumping to a higher dose too fast is the most common reason people abandon GLP-1 therapy. The nausea becomes unmanageable, they stop, and they conclude the medication doesn’t work for them. It usually does work. They just went too fast.

Your provider at Mochi can slow the escalation if you’re struggling. If you’re tolerating each dose well and not losing weight after 12 weeks, they can also push faster. The protocol is a guide, not a law.

One thing worth knowing: the 2.4mg maintenance dose is where the weight loss data gets most compelling. The STEP 5 trial (Garvey et al., Obesity, 2022) followed participants at 2.4mg semaglutide for 104 weeks and showed sustained weight loss of 15.2% from baseline. You’re not going to hit that number in month two at 0.25mg. The timeline is longer than most people expect.

How should you measure progress in the first few months?

Not by the scale alone. This is where a lot of people go wrong.

Weight fluctuates 2 to 4 pounds day to day based on water, food volume, and hormones. Weighing yourself daily and graphing the trend is more useful than checking once a week and panicking at the number. Apps like Happy Scale average your weigh-ins and show the trend line. Use that.

Better metrics in months one and two:

• How your clothes fit, specifically waistbands
• Blood pressure if yours was elevated
• Energy levels and sleep quality
• Hunger between meals (this is the clearest early signal the medication is working)

The scale will move, but probably not as fast as you want. A realistic expectation at 0.25mg to 0.5mg is 1 to 2 pounds per week if you’re also eating thoughtfully. Some weeks you’ll lose nothing and then drop 3 pounds the following week. That’s normal.

Protein intake matters more than most people realize during this phase. When you’re eating less, your body can lose muscle alongside fat if you’re not getting enough protein. Research from Cava et al. (Nutrients, 2017) showed that higher protein intake during caloric restriction preserves lean mass. Aim for at least 100g daily, even if your appetite is suppressed.

Is compounded semaglutide safe to use?

Compounded semaglutide has been a contested topic since Ozempic and Wegovy shortages created an opening for 503A and 503B pharmacies to fill demand. The FDA has maintained that compounded drugs aren’t FDA-approved, which is true and worth knowing. It doesn’t mean compounded semaglutide is ineffective or inherently unsafe.

503B outsourcing facilities operate under stricter federal standards than 503A compounding pharmacies. They’re registered with the FDA, subject to current Good Manufacturing Practice (cGMP) requirements, and can compound drugs during shortage periods for patient-specific prescriptions. If you’re using a telehealth platform that sources from a 503B facility, that’s a meaningful distinction.

I moved to a compounded GLP-1 provider after my PCP declined to prescribe and three months of prior authorization appeals went nowhere. At the time I started, I was at 247 pounds. Six months in, I’m at 209. I’m not a doctor and I can’t tell you that path is right for you, but I can tell you the medication sourced through a licensed 503B facility worked the same way the clinical literature describes.

The FDA issued guidance in 2024 clarifying its position on compounded semaglutide, specifically noting concerns about salt forms (semaglutide sodium and acetate) rather than the base molecule. If your pharmacy is using semaglutide base, that guidance doesn’t apply the same way. Ask your provider directly.

What Mochi doesn’t tell you upfront

The membership fee doesn’t include medication. You pay $99/month for the platform and provider access, then separately for the compounded medication, which runs roughly $200 to $400/month depending on dose and pharmacy. That’s still far below the $1,300+ monthly list price for brand-name Wegovy without insurance, but the all-in cost is higher than the headline number suggests.

The dietitian access is asynchronous for most members. You’re messaging, not scheduling live video calls. That works fine for some people and is frustrating for others. Know what you’re getting before you sign up.

If your insurance covers brand-name Wegovy or Zepbound, that path may be cheaper. The Novo Nordisk savings program has brought Wegovy to $0 for eligible commercially insured patients. Worth checking before you default to compounded.

If you’re uninsured or your PCP won’t engage with obesity medicine, a telehealth platform like Mochi or a compounded GLP-1 service is often the most practical route to accessing this class of medication at a price that doesn’t require financing.

Frequently asked questions

Does Mochi Health use real semaglutide?

Yes. Mochi prescribes compounded semaglutide, which contains the same active ingredient as Ozempic and Wegovy. It’s not an FDA-approved branded product, but the active molecule is semaglutide. Sourcing matters: ask whether the pharmacy is a 503B outsourcing facility.

How long before semaglutide starts working?

Most people notice reduced appetite within the first two weeks at 0.25mg. Measurable weight loss typically shows up by weeks 4 to 6. The full effect at the maintenance dose of 2.4mg takes 6 to 12 months to materialize. Expecting dramatic results in month one sets you up for disappointment.

Can I use Mochi if my doctor refused to prescribe GLP-1s?

Yes. Telehealth platforms including Mochi operate independently of your primary care physician. You’ll complete an intake, provide medical history, and be evaluated by a provider on the platform. Whether you qualify depends on your BMI and health profile, not your PCP’s opinion.

What’s the difference between Mochi and Orderly Meds?

Orderly Meds is a lighter-touch model: lower friction, less coaching, closer to a direct pharmacy relationship. Mochi includes more structured clinical oversight and dietitian access. If you want accountability and check-ins, Mochi is more suited to that. If you want a prescription with minimal overhead, Orderly Meds fits better.

How do I handle nausea in the first month?

Small meals, low-fat foods, consistent injection timing, and hydration are the four levers you have. Ginger tea and B6 supplements have anecdotal support. If nausea is severe enough to prevent eating, contact your provider. They can slow the escalation or recommend an antiemetic. Don’t push through to a higher dose while actively symptomatic.

Is the Mochi dietitian actually useful?

Depends on how much you engage. The messaging-based format works well if you have specific questions about protein targets, meal timing, or navigating social eating. It’s not a substitute for a weekly session with a registered dietitian who knows your full history. Treat it as a resource, not a therapy relationship.

Can I switch from Mochi to another provider?

Yes. Your prescription is tied to Mochi’s platform, but your medical records are yours. If you move to a different telehealth service or a compounded GLP-1 provider, you can request records and pick up roughly where you left off. There’s no lock-in beyond your membership billing cycle.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. “Once-weekly semaglutide in adults with overweight or obesity.” New England Journal of Medicine. 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Garvey WT, Batterham RL, Bhatta M, et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.” Obesity. 2022. https://doi.org/10.1002/oby.23454
3. Cava E, Yeat NC, Mittendorfer B. “Preserving healthy muscle during weight loss.” Advances in Nutrition. 2017. https://doi.org/10.3945/an.116.014506
4. U.S. Food and Drug Administration. “Compounding and the FDA: Questions and answers.” FDA.gov. Updated 2024. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
5. U.S. Food and Drug Administration. “FDA updates on compounded semaglutide.” FDA.gov. 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss